Do analysts rate SYBX or IMA?

ImageneBio has a consensus target price of $29.00, indicating a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Is SYBX or IMA more profitable?

Synlogic's return on equity of -26.47% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% ImageneBio N/A -38.99% -34.84%

Does the media refer more to SYBX or IMA?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat ImageneBio's score of 0.00 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SYBX or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SYBX or APLM?

Apollomics has higher revenue and earnings than Synlogic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synlogic $8K 1,760.79 -$23.36M -$0.06 N/A Apollomics $8.50M 7.89 -$10.94M N/A N/A

Is SYBX or APLM more profitable?

Apollomics' return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Apollomics N/A N/A N/A

Do analysts prefer ELTX or SYBX?

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 956.15%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELTX or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Synlogic N/A -26.47% -18.00%

Does the media favor ELTX or SYBX?

In the previous week, Elicio Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.93 beat Elicio Therapeutics' score of 0.34 indicating that Synlogic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SYBX or TVGN?

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,188.49%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SYBX or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Tevogen Bio N/A N/A -468.32%

Does the media refer more to SYBX or TVGN?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat Tevogen Bio's score of 0.00 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SYBX or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SYBX or BKHA?

Black Hawk Acquisition has lower revenue, but higher earnings than Synlogic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synlogic $8K 1,760.79 -$23.36M -$0.06 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is SYBX or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Black Hawk Acquisition N/A N/A N/A

Does the media refer more to SYBX or BKHA?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat Black Hawk Acquisition's score of 0.35 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Synlogic (SYBX) Competitors

$1.15 0.00 (0.00%)

As of 09/23/2026 03:46 PM Eastern

Compare

SYBX vs. IMA, APLM, ELTX, TVGN, and BKHA

Should you buy Synlogic stock or one of its competitors? Synlogic's main competitors and comparable companies include ImageneBio (IMA), Apollomics (APLM), Elicio Therapeutics (ELTX), Tevogen Bio (TVGN), and Black Hawk Acquisition (BKHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Synlogic compare to ImageneBio?

Synlogic (NASDAQ:SYBX) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat ImageneBio's score of 0.00 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synlogic has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Synlogic's return on equity of -26.47% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
ImageneBio	N/A	-38.99%	-34.84%

Synlogic has higher earnings, but lower revenue than ImageneBio. Synlogic is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A
ImageneBio	$800K	69.06	-$45.35M	-$4.58	N/A

63.4% of Synlogic shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 2.2% of ImageneBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ImageneBio has a consensus target price of $29.00, indicating a potential upside of 495.73%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

ImageneBio beats Synlogic on 8 of the 15 factors compared between the two stocks.

How does Synlogic compare to Apollomics?

Synlogic (NASDAQ:SYBX) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has higher revenue and earnings than Synlogic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A

In the previous week, Synlogic had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Synlogic and 0 mentions for Apollomics. Synlogic's average media sentiment score of 0.93 beat Apollomics' score of 0.00 indicating that Synlogic is being referred to more favorably in the media.

Company	Overall Sentiment
Synlogic	Positive
Apollomics	Neutral

63.4% of Synlogic shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Apollomics	N/A	N/A	N/A

Synlogic has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Summary

Synlogic and Apollomics tied by winning 5 of the 10 factors compared between the two stocks.

How does Synlogic compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Elicio Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.93 beat Elicio Therapeutics' score of 0.34 indicating that Synlogic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Synlogic's return on equity of -26.47% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Synlogic	N/A	-26.47%	-18.00%

Synlogic has higher revenue and earnings than Elicio Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 956.15%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Elicio Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elicio Therapeutics and Synlogic tied by winning 7 of the 14 factors compared between the two stocks.

How does Synlogic compare to Tevogen Bio?

Synlogic (NASDAQ:SYBX) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

63.4% of Synlogic shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 65.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat Tevogen Bio's score of 0.00 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Tevogen Bio	N/A	N/A	-468.32%

Synlogic has higher revenue and earnings than Tevogen Bio. Synlogic is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Synlogic has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,188.49%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Synlogic beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.

How does Synlogic compare to Black Hawk Acquisition?

Synlogic (NASDAQ:SYBX) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Black Hawk Acquisition's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Black Hawk Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

63.4% of Synlogic shares are owned by institutional investors. 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Synlogic has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Black Hawk Acquisition has lower revenue, but higher earnings than Synlogic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,760.79	-$23.36M	-$0.06	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.93 beat Black Hawk Acquisition's score of 0.35 indicating that Synlogic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synlogic beats Black Hawk Acquisition on 5 of the 7 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.09M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-4.42	13.88	274.08	25.69
Price / Sales	1,760.79	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.06	15.40	10.47	6.32
Net Income	-$23.36M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.86%	-1.70%	-0.67%	0.17%
1 Month Performance	-2.54%	-6.17%	-3.17%	-3.27%
1 Year Performance	-32.55%	30.67%	15.14%	5.58%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	0.3436 of 5 stars	$1.15 flat	N/A	-33.7%	$14.09M	$8K	N/A	80
IMA ImageneBio	2.6502 of 5 stars	$4.93 +0.2%	$29.00 +488.2%	-38.8%	$55.85M	$800K	N/A	18	Gap Up
APLM Apollomics	1.1627 of 5 stars	$21.88 -8.9%	N/A	+25.1%	$52.75M	$8.50M	N/A	45	Gap Down
ELTX Elicio Therapeutics	2.5287 of 5 stars	$1.77 -11.1%	$19.75 +1,015.8%	-83.2%	$52.30M	N/A	N/A	N/A	News Coverage Positive News Gap Down
TVGN Tevogen Bio	1.0408 of 5 stars	$7.80 +0.6%	$100.00 +1,182.1%	-80.6%	$50.46M	N/A	N/A	3	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. IMA, APLM, ELTX, TVGN, and BKHA

How does Synlogic compare to ImageneBio?

Summary

How does Synlogic compare to Apollomics?

Summary

How does Synlogic compare to Elicio Therapeutics?

Summary

How does Synlogic compare to Tevogen Bio?

Summary

How does Synlogic compare to Black Hawk Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. IMA, APLM, ELTX, TVGN, and BKHA

How does Synlogic compare to ImageneBio?

Does the media refer more to SYBX or IMA?

Which has more risk & volatility, SYBX or IMA?

Is SYBX or IMA more profitable?

Which has higher valuation & earnings, SYBX or IMA?

Do insiders and institutionals believe in SYBX or IMA?

Do analysts rate SYBX or IMA?

Summary

How does Synlogic compare to Apollomics?

Do analysts prefer SYBX or APLM?

Which has stronger valuation and earnings, SYBX or APLM?

Does the media refer more to SYBX or APLM?

Do insiders and institutionals believe in SYBX or APLM?

Is SYBX or APLM more profitable?

Which has more volatility and risk, SYBX or APLM?

Summary

How does Synlogic compare to Elicio Therapeutics?

Does the media favor ELTX or SYBX?

Is ELTX or SYBX more profitable?

Which has stronger valuation and earnings, ELTX or SYBX?

Do analysts prefer ELTX or SYBX?

Which has more risk & volatility, ELTX or SYBX?

Do insiders & institutionals hold more shares of ELTX or SYBX?

Summary

How does Synlogic compare to Tevogen Bio?

Do institutionals & insiders have more ownership in SYBX or TVGN?

Does the media refer more to SYBX or TVGN?

Is SYBX or TVGN more profitable?

Which has higher valuation & earnings, SYBX or TVGN?

Which has more risk & volatility, SYBX or TVGN?

Do analysts recommend SYBX or TVGN?

Summary

How does Synlogic compare to Black Hawk Acquisition?

Is SYBX or BKHA more profitable?

Do analysts prefer SYBX or BKHA?

Do insiders and institutionals have more ownership in SYBX or BKHA?

Which has more volatility and risk, SYBX or BKHA?

Which has stronger valuation and earnings, SYBX or BKHA?

Does the media refer more to SYBX or BKHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools